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Abstract
BACKGROUND—Reducing breast cancer incidence and achieving equity in breast cancer 
outcomes remains a priority for public health practitioners, health care providers, policy makers, 
and health advocates. Monitoring breast cancer survival can help evaluate the effectiveness of 
health services, quantify inequities in outcomes between states or population subgroups, and 
inform efforts to improve the effectiveness of cancer management and treatment.
METHODS—We analyzed breast cancer survival using individual patient records from 37 
statewide registries that participated in the CONCORD-2 study, covering approximately 80% of 
the US population. Females were diagnosed between 2001 and 2009 and were followed through 
December 31, 2009. Age-standardized net survival at 1 year, 3 years, and 5 years after diagnosis 
was estimated by state, race (white, black), stage at diagnosis, and calendar period (2001–2003 
and 2004–2009).
RESULTS—Overall, 5-year breast cancer net survival was very high (88.2%). Survival remained 
remarkably high from 2001 through 2009. Between 2001 and 2003, survival was 89.1% for white 
females and 76.9% for black females. Between 2004 and 2009, survival was 89.6% for white 
females and 78.4% for black females.
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CONCLUSIONS—Breast cancer survival was more than 10 percentage points lower for black 
females than for white females, and this difference persisted over time. Reducing racial disparities 
in survival remains a challenge that requires broad, coordinated efforts at the federal, state, and 
local levels. Monitoring trends in breast cancer survival can highlight populations in need of 
improved cancer management and treatment.
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INTRODUCTION
The burden of breast cancer has been a persistent concern among public health practitioners, 
health care providers, policy makers, and health advocates. Worldwide, breast cancer is the 
second most common cancer and the fifth leading cause of cancer deaths among females.1 In 
the United States, breast cancer is the most commonly diagnosed cancer (excluding skin 
cancer) and the second leading cause of cancer deaths among females.2 Since early 2004, 
breast cancer incidence has been stable, whereas breast cancer mortality has been 
decreasing.3 However, these trends have not been equal among all populations.3
The elimination of health disparities is a goal of many federal agencies. For example, the 
US. Department of Health and Human Services, the Agency for Healthcare Research and 
Quality, and the Centers for Disease Control and Prevention (CDC) have developed action 
plans to reduce health disparities.4–7 Unequal incidence of advanced-stage breast cancer, 
receipt of high-quality treatment, and breast cancer death rates have not changed much over 
time.5,8 Breast cancer incidence rates have historically been higher among white females, 
while mortality rates have been higher among black females. The annual average percentage 
change in incidence from 1999 through 2013 varied by race, with a 0.8% decrease per year 
among white females and a 0.4% increase per year among black females.9 Breast cancer 
mortality rates have fallen since the mid-1990s to 2012 among both black and white females, 
but the rate of decline has been faster among white females (annual percentage change, 
−1.9% vs −1.5%).10–12 Although there have been great advancements in treatment options, 
racial inequalities in breast cancer survival in the United States still persist.
An evaluation of population-based survival trends can help to inform cancer-control efforts 
by identifying opportunities for improvement in early detection, diagnosis, and treatment. 
Population-based survival is a key measure of the effectiveness of cancer management and 
treatment.13 Black females are more often diagnosed with regional or late-stage disease and 
have higher death rates than white females, regardless of stage.14 In 2008, the CONCORD 
study reported 5-year population-based survival in 31 countries, including 22 registries in 16 
US states.15 Five-year survival in North America was among the highest in the world at 
84%, with large survival differences between white (84.7%) and black (70.9%) females in 
the United States, suggesting that black females may not have the same access to and quality 
of care as white females. The second cycle of the CONCORD program (CONDORD-2) 
examined survival from 10 common cancers in 67 countries.16 CONCORD-2 is the largest 
study of population-based cancer survival trends to date, evaluating trends in 5-year survival 
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for over 25 million individual patients diagnosed during the 15 years between 1995 and 
2009. Age-standardized, 5-year net survival from breast cancer increased in many countries 
worldwide. In the United States, it rose from 86% between 1995 and 1999 to 88.6% between 
2005 and 2009.
This report describes trends in net survival in a population-based setting (ie, the survival for 
all females with breast cancer) after controlling for competing risks of death. Net survival 
allows us to estimate and compare survival for females with breast cancer between countries 
or states without using the cause of death, which is often unreliable or not comparable 
between different states. By using the US data from CONCORD-2, we examined the 
distribution of breast cancer stage at diagnosis by race, state, and over time. We also 
analyzed survival trends by race, stage, and state. This study provides information on the 
effectiveness of the US health system in managing females with breast cancer from 
diagnosis to the final outcome. This analysis is part of the largest population-based study of 
cancer survival trends in the United States, including over 10 million patients with cancer.
MATERIALS AND METHODS
Data
We used data from 37 state cancer registries funded by either the CDC’s National Program 
of Cancer Registries (NPCR), the National Cancer Institute’s Surveillance, Epidemiology, 
and End Results (SEER) program, or both. These registries participated in the CONCORD-2 
study,17 which covered approximately 80% of the US population. Registries consented to the 
inclusion of their data in the more detailed analyses reported here. We analyzed individual 
tumor records for 1,372,377 females (ages 15–99 years) who were diagnosed with breast 
cancer (International Classification of Diseases for Oncology, third edition,18 codes C50.0-
C50.6 and C50.8-C50.9) between 2001 and 2009 and were followed until December 31, 
2009. We included primary invasive cancers of the breast, regardless of whether the woman 
had a previous cancer. If a woman was diagnosed with ≥2 cancers of the breast between 
2001 and 2009, then only the first was considered in the survival analyses. All races were 
included in the study, but we only reported separate survival for blacks and whites because 
of the small numbers for the other races in many states. Females who were excluded from 
the data were those who were registered from a death certificate only, were lost to follow-up, 
had inconsistent site-morphology combinations, or had invalid dates.16
Patients were grouped by year of diagnosis into 2 calendar periods (2001–2003 and 2004–
2009) to reflect changes in the methods used by US registries to collect data on stage at 
diagnosis. From 2001, most registries coded stage directly from the source data to SEER 
Summary Stage 2000 (SS2000).19 From 2004, all registries began to derive SS2000 using 
the Collaborative Stage unified data collection system.20
Survival Analyses
We estimated net survival up to 5 years after diagnosis and 95% confidence intervals (CIs) 
using the Pohar Perme estimator.21 We analyzed survival by race, stage at diagnosis, 
calendar period of diagnosis, and US state. Net survival is the probability of surviving up to 
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a given time since diagnosis, after controlling for other causes of death (background 
mortality). In other words, it is the probability that females with breast cancer will survive 
their cancer. The certified cause of death and the cause coded as the underlying cause of 
death are often unreliable or not comparable between different states. The risk of death from 
causes other than the breast cancer (competing risks of death, or background mortality) also 
varies widely between populations and over time. To control for the wide differences in 
background mortality among participating states while estimating net survival, we 
constructed life tables of all-cause mortality in the general population of each state from the 
number of deaths and the population, by single year of age, sex, calendar year, and, where 
possible, by race (black, white), using a flexible Poisson model.22 Methods for constructing 
the life tables have been published.23
We estimated net survival using the cohort approach for females diagnosed between 2001 
and 2003, because they all had been followed for at least 5 years by December 31, 2009. We 
used the complete approach to estimate net survival for females diagnosed between 2004 
and 2009, because 5 years of follow-up data were not available for all females. Net survival 
was estimated for 5 age-groups (ages 15–44, 45–54, 55–64, 65–74, and 75–99 years). We 
obtained age-standardized survival estimates using the International Cancer Survival 
Standard weights.24 If 2 or more of the 5 age-specific estimates could not be obtained, then 
we present only the pooled, unstandardized survival estimate for all ages combined. Trends, 
geographic variations, and differences in age-standardized survival by race are presented 
graphically in bar charts and funnel plots.25 More details on data and methods are provided 
in an accompanying article.26
RESULTS
There were 1,372,377 US females (85.1% white females and 10.4% black females) 
diagnosed with breast cancer in participating registries between 2001 and 2009. Overall, 
there were no substantial changes in SEER Summary Stage distribution between the 2001 
through 2003 and 2004 through 2009 periods (Table 1). Between 2001 and 2003, most 
breast cancers were diagnosed at local stage (60%), approximately 30% were regional stage, 
and <5% were distant stage. The proportion of females with unknown stage was low at 7%. 
The distribution remained similar between 2004 and 2009, exhibiting a slight reduction in 
the percentage of cancers of unknown stage cancer. The stage distribution varied slightly 
between states (Supporting Table 1). During both calendar periods of diagnosis, a lower 
proportion of black females were diagnosed at local stage, and the proportion of distant 
stage was about 1.6 times that of white females.
Survival decreased with time after diagnosis. Survival at 3 years was lower than at 1 year 
after diagnosis, and survival at 5 years was lower than at 3 years after diagnosis in both time 
periods (Table 2). Between 2001 and 2003, breast cancer 5-year net survival for all races 
combined was high at 88.2%, and it remained high at 88.6% between 2004 and 2009. 
Overall, the difference in 5-year survival between black females and white females was 
greater than 10 percentage points between 2001 and 2003, and this disparity did not decrease 
over time. Between 2004 and 2009, survival varied widely between states (range, 85.4%–
92.4%), and it was systematically lower for black females (Supporting Table 2).
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Five-year net survival was high for females who were diagnosed with local stage cancer 
between 2001 and 2003 at 98% and remained high for those who were diagnosed between 
2004 and 2009 (Table 3). In both periods, the difference in survival between white females 
and black females was highest for those with regional tumors (82.3% and 83.5%, 
respectively, for white females vs 69.9% and 71.8%, respectively, for black females) and 
distant tumors (22.5% and 25.7%, respectively, for white females vs 15.2% and 17.1%, 
respectively, for black females). This difference was noticed in all states and did not 
decrease over time (Supporting Table 3). For local stage, the racial disparity persisted but to 
a smaller extent (98.2% and 98.6%, respectively, for white females vs 92.8% and 94.3%, 
respectively, for black females).
Figure 1 illustrates 5-year age-standardized net survival by state. Between 2001 and 2003, 5-
year survival for breast cancer was very high at approximately 90%. Survival remained high 
between 2004 and 2009, with slight variation between states and regions. There was a 0.5% 
increase in net survival across the United States. The change in survival among states ranged 
from −2.9% to 3.6%.
Figure 2 provides funnel plots of net survival for the periods 2001 through 2003 and 2004 
through 2009 to provide further insight into the variability of breast cancer survival in the 
United States by race and state. The plots reveal how much a particular survival estimate 
deviates from the pooled US value (the “target,” represented in the plot by the horizontal 
line) given the precision of each estimate.24,25 These plots indicate striking geographic and 
racial variation in survival. Between 2001 and 2003, net survival was lower for black 
females in all states. Although survival for black females increased slightly between 2004 
and 2009, it remained lower for black females compared with white females in most states. 
Also in most states, survival for white females was above the pooled US estimate, whereas 
survival for all black females was below the pooled US estimate.
DISCUSSION
The current study is the largest study to date on trends in population-based breast cancer 
survival in the United States. It is also unique, in that the data are analyzed by race, stage at 
diagnosis, and state. This expands the US results from CONCORD-2 by providing a detailed 
analysis of net survival by race and stage at diagnosis. Population-based survival is a key 
measure of the overall effectiveness of the health system in dealing with cancer and thus is a 
useful measure for evaluating access to and quality of care and appropriate treatment. These 
results can be used to plan future cancer-control strategies.
Overall survival for breast cancer was strikingly high between 2001 and 2003 and remained 
high between 2004 and 2009. There was wide variability in survival between states, with 
lower survival for black than for white females in all 37 states included in the analyses. 
Disappointingly, the greater than 10% difference in survival between white and black 
females did not improve over time. More efforts need to be initiated to understand the 
reasons for this persistent racial disparity in breast cancer survival and to help black females 
in accessing early diagnosis and appropriate treatment.
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Black/white inequalities in survival suggest differences in access to care and in tumor 
morphology between the groups. Within the same stage of disease, net survival is lower 
among black females. However, black/white differences in mammography rates by state are 
not consistent with stage of disease or survival. Indeed, there were no significant state-
specific differences between black and white females who reported having had a 
mammogram within the past 2 years during the study periods.27
Clinical Perspective
Having access to diagnostic studies and high-quality treatment is important for improving 
breast cancer survival. Black females are more likely than white females to experience 
delays in treatment and not to receive appropriate treatment for breast cancer.28 Delays in 
care and inappropriate treatment can result in larger tumors and poorer outcomes. Timely 
follow-up of abnormal test results and receipt of treatment after diagnosis could improve 
outcomes of all females with breast cancer.29 Access to quality care is a key factor to 
reducing disparities in breast cancer survival.
Breast cancer is a very heterogeneous disease. There are several different types of breast 
cancer with multiple subtypes based on biomarkers, such as estrogen receptor, progesterone 
receptor, and human epidermal growth factor receptor status. Differences in tumor 
morphology not only dictate treatment but also are prognostic. For example, triple-negative 
breast cancer (a breast cancer subtype that does not have estrogen receptor, progesterone 
receptor, or HER2 protein) is a more aggressive tumor with lower survival and is diagnosed 
more often among black females.30,31 There may be other tumor characteristics or 
underlying biologic differences between black and white females impacting tumor 
progression or therapy response that could be contributing to the observed survival 
differences by race.
Research is continually identifying new tumor bio-markers that have potential for use in a 
clinical setting. As treatment becomes more individualized, not all options are always 
available to all patients. Therefore, as newer treatments improve survival, it may not improve 
survival equally among all females. If minority or low-income females do not have access to 
newer treatment options, then survival improvements may not be as apparent among these 
groups in population-based surveillance systems. This may be 1 reason why we see that, at 
the same stage of diagnosis, net survival is lower among black than among white females.
Cancer-Control Perspective
In addition to addressing potential racial differences in the clinical care for breast cancer to 
reduce racial breast cancer survival disparities, there are several health behavior factors that 
can reduce the risk for breast cancer.32–35 Modifying risk factors, such as obesity, lack of 
physical activity, alcohol consumption, exposure to environmental toxins, and use of 
hormone therapy, can reduce a woman’s risk of getting breast cancer. Black females often 
have more comorbid conditions, which put them at greater risk for poorer survival outcomes.
36
 Women who may be at high risk for breast cancer because of family history or genetic 
reasons may need enhanced screening and risk-reduction procedures, such as taking 
antiestrogens or undergoing prophylactic mastectomy. Minority and low-income females 
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more often have limited access to these options,37,38 which ultimately may put them at 
increased risk of dying from breast cancer.
Once diagnosed with breast cancer, females need to be educated and empowered to take part 
in treatment decisions and to receive timely, guideline-concordant, and complete treatment. 
Females who have lack of trust in the health care system or who are characterized by 
cultural differences from their health care providers may not receive the needed treatment 
and supportive care.39 Studies that analyzed the availability of equal treatment among all 
patients demonstrated that patients have similar outcomes when they receive equal 
treatment.40–43 This suggests that the large and persistent survival deficit in black females 
between 2001 and 2009 may be attributable to the receipt of less effective treatment. 
Supportive care is also an area that needs more attention. Specifically, interventions to 
address geographic isolation, cultural differences, financial burden, and fear may be needed 
to improve access to quality care. These issues may be addressed along with clinical care.
Strengths and Limitations
This is the largest study comparing breast cancer survival by state and race using data from 
CONCORD-2, which include high-quality data covering greater than 80% of the US 
population. In addition, for females diagnosed with breast cancer, 98.9% of cases were 
morphologically verified, and the percentage of cases with unknown stage was low.44 All 
participating registries were certified by the North American Association of Central Cancer 
Registries as having met data quality and completeness standards (available at: http://
www.naaccr.org/Certification/Criteria.aspx, Accessed June 28, 2017).
The current study had a few limitations. First, the follow-up procedures in the United States 
differed according to the federal funding source.45 All SEER registries are required to 
conduct follow-up of all cases to ascertain vital status. NPCR registries are only funded to 
ascertain deaths through linkage with the state vital records and the National Death Index. 
Some state cancer registries assumed that a patient was alive if the case was not included on 
a state death certificate database or on the National Death Index. Second, the manner in 
which SEER SS2000 data were collected and reported changed for all registries in 2004, as 
described above (see Methods). This resulted in a decrease in the percentage of cases with 
unknown stage when stage was derived rather than manually coded. Next, the states in the 
Western Region (Mountain and Pacific Divisions) had too few black females to reliably 
assess racial differences, and some states did not report stage data, which could result in the 
data not being generalizable to the entire United States. Further, we were only able to report 
on black and white women due to low numbers of other races in most states. Finally, vital 
status follow-up data were only available through December 31, 2009; therefore, we did not 
have 5-year follow-up for each patient. Because the remarkable differences between black 
and white females have persisted for more than a decade in this study, they are unlikely to 
simply disappear with the inclusion of more recent years of follow-up data. The third cycle 
of the CONCORD program is ongoing, and the data set is currently being updated. This will 
include patients who were diagnosed and followed until the end of 2014.
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Conclusion
There is increasing awareness and effort to achieve health equity among racial, ethnic, 
geographic, socioeconomic, and other groups. With the persistent disparity in breast cancer 
survival between black females and white females, more national, local, and individual 
efforts are needed. This study provides accurate, useful information on incidence and 
survival of breast cancer patients in various US subpopulations and is supported through a 
nation-wide system of central cancer registries funded by the CDC’s NPCR or the National 
Cancer Institute’s SEER program.45
The CDC and its partners are dedicated to identifying and addressing the factors that lead to 
health disparities among racial, ethnic, geographic, socioeconomic, and other groups so that 
barriers to health equity can be removed. The CDC’s National Breast and Cervical Cancer 
Early Detection Program works with the states, tribes/tribal organizations, and territories to 
provide assistance to low-income females to ensure that they have access to appropriate 
breast and cervical cancer screening, diagnostic, and treatment services.45 The CDC’s 
Comprehensive Cancer Control Program works with states, tribes/tribal programs, and 
territories to develop cancer-control plans that focus on prevention, screening, and 
survivorship issues.45 Working with partner organizations, such as the National African 
American Tobacco Prevention Network and the National Alliance for Hispanic Health, these 
programs target specific populations who are at risk of developing or dying from cancer.
Eliminating or reducing disparities in breast cancer survival will require broad, coordinated 
population efforts at various federal, state, and local levels. The persistent black/white 
disparities in breast cancer survival reported here demonstrate that increased focus on 
individual, provider, community, organizational, and policy levels are warranted. Public 
health has an important opportunity to expand outreach to medically underserved females, 
provide education about breast cancer risk reduction, and increase awareness about post-
treatment strategies to improve outcomes. Evidence-based interventions to further improve 
provider awareness, knowledge, and practice also need to be identified. Finally, public health 
professionals can champion community-level engagement and partnerships to leverage 
organizational infrastructure and provide evidence to inform organizational policies that 
ensure equal cancer care among all females and a reduction in breast cancer survival 
disparities. Focusing on education and informed decisions, cultural sensitivities, 
personalized care, and equal access to care are critical steps.
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Figure 1. 
Breast cancer 5-year age-standardized net survival (%) is illustrated for females (ages 15–99 
years) diagnosed 2001–2003 and 2004–2009 along with absolute changes (%). States are 
grouped by US Census region. Note that data from 37 statewide cancer registries (covering 
80.6% of the population) are ranked within US Census region by the survival estimate for 
2004–2009. Dark bars denote states funded by the Centers for Disease Control and 
Prevention National Program of Cancer Registries; pale bars, states funded by the National 
Cancer Institute’s Surveillance, Epidemiology and End Results Program. Asterisks indicate 
states that are funded by both federal surveillance programs. Change (%) was not plotted if a 
survival estimate was not available for 1 calendar period or if 1 or more estimates were not 
age standardized.
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Figure 2. 
Breast cancer 5-year age-standardized net survival (%) is illustrated for females (ages 15–99 
years) by state, race, and calendar period of diagnosis. Note that the pooled US survival 
estimate for each calendar period is indicated by the solid horizontal line with corresponding 
95.0% and 99.8% control limits (dashed lines).
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